Core Viewpoint - Hydreight Technologies Inc. announces a normal course issuer bid to purchase up to 4,951,189 common shares, representing approximately 9.27% of the outstanding shares, to enhance shareholder value and stabilize market pricing [1] Company Overview - Hydreight Technologies Inc. is a provider of digital health infrastructure and on-demand healthcare services across the United States, aiming to build one of the largest mobile clinic networks [1] - The company has developed a proprietary platform that connects over 3,000 nurses and 300 doctors, facilitating healthcare services directly to patients in various settings [1] - Hydreight's platform includes integrated tools for managing patient data, accounting, and sales, empowering healthcare professionals to operate independently [1] Normal Course Issuer Bid Details - The issuer bid will commence on March 12, 2026, and terminate on March 11, 2027, or earlier if completed [1] - The bid will be conducted in accordance with applicable securities laws and will be funded from existing working capital [1] - The company believes that the current market price does not reflect its business strength and growth potential, justifying the share buyback [1] VSDHOne Platform - Hydreight launched the VSDHOne platform in partnership with Victory Square Technologies, aimed at simplifying entry for businesses into the online healthcare space [1] - The platform offers compliant healthcare services, including GLP-1s, peptides, and personalized treatments, allowing businesses to launch direct-to-consumer healthcare brands quickly [1] - VSDHOne provides a comprehensive solution, reducing the time and costs associated with entering the online healthcare market [1]

Core Viewpoint - Hydreight Technologies Inc. has provided revenue guidance for fiscal year 2026, projecting approximately $150 million in revenue, which reflects a conservative baseline outlook based on contracted demand and partner activity [2][6]. Fiscal 2026 Revenue Guidance - The company expects fiscal 2026 revenue of around $150 million, which is a conservative estimate based on existing pharmacy operations and digital health platform activities [2]. - This guidance does not include potential contributions from acquisitions, new market entries, or additional commercial arrangements that are not currently operational [2][6]. Q1 2026 Revenue Outlook - For the first quarter of fiscal 2026, the company anticipates revenue between $25 million and $28 million, driven by major partnerships and pharmacy product lines that are set to go live [3]. Cost Structure, Margin, and Profitability Context - The fiscal 2026 guidance assumes no significant increase in fixed operating costs compared to late 2025 levels, with revenue growth supported by the existing cost base [4]. - The company expects an Adjusted EBITDA margin of approximately 15-17%, benefiting from scaling transaction volumes across a largely fixed operating cost structure [5]. Management Commentary - The CEO of Hydreight emphasized that the guidance reflects the visibility into operations and is grounded in existing demand, supported by a disciplined cost structure [7]. Capital Position - The company recently completed a $15 million financing deal to enhance working capital, which is expected to support anticipated transaction volumes and ongoing operations [9].

Core Insights - Hydreight Technologies Inc. has exceeded its operational target for 2025 by surpassing 1.3 million product orders placed ahead of year-end, reflecting strong platform adoption and partner demand [4][10][11] - The company has expanded its ecosystem to approximately 2,500 licenses, significantly exceeding its target of 1,000 for 2025, although many licenses are still in onboarding stages [7][10] - The focus remains on long-term value creation and disciplined execution as the company prepares for increased platform activity in 2026 [9][10][15] Operational Highlights - VSDHOne, the enterprise-focused vertical, began commercial activity in late June 2025 and has been progressively scaled [3] - The company achieved over 1.3 million product orders placed, surpassing its 2025 operational target, driven primarily by an initial base of approximately 400 fully onboarded licenses [4][10] - Hydreight continues to use product orders placed as its primary operational metric, reflecting real-time platform activity and demand [5][23] License and Platform Expansion - The company supports around 2,500 licenses, with the majority still in onboarding or early activation stages, which are not yet contributing significantly to order volume [7][10] - Management anticipates that utilization will scale progressively as onboarding is completed, positioning the company for increased activity in 2026 [7][15] Average Order Value and Strategic Focus - Average order value (AOV) reflects the early-stage scaling of newer offerings, with a focus on balancing order volume and product mix for long-term value creation [9][10] - The company is committed to building a durable and scalable business, with expectations for platform metrics to evolve as newer verticals mature [10] 2026 Guidance and Future Outlook - Hydreight plans to provide formal 2026 guidance early in the new year, following a review of several strategic initiatives, including enterprise partnerships and M&A opportunities [12][14] - The company is evaluating late-stage opportunities for enterprise customers, which will be incorporated into future guidance for a more accurate business outlook [13][14] Recognition and Growth - Hydreight was ranked as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ and recognized as a top 50 TSX Venture Exchange company [16] - The company is expanding high-volume platform partners and increasing utilization across multiple healthcare categories, while also strengthening compliance and governance [16]

Core Insights - Hydreight Technologies Inc. reported a 132% year-over-year revenue increase in Q3 2025, marking its fourth consecutive quarter of profitability, driven by a diversified multi-vertical business model [3][6][23] Financial Performance - Q3 2025 GAAP revenue reached $10.52 million, a 132% increase compared to Q3 2024 - Topline revenue for Q3 was $12.83 million, up 110% year-over-year - Gross margin for Q3 was $2.33 million, an increase from $1.53 million in Q3 2024 - Adjusted EBITDA for Q3 was $620K, indicating continued operational improvement - GAAP net income for Q3 was $362K, compared to a net loss of $90K in Q3 2024 - For the first nine months of 2025, topline revenue was $26.71 million, up 61% year-over-year, and GAAP revenue was $20.44 million, up 70% year-over-year [6][8][23] Business Model and Growth - Hydreight operates a multi-vertical platform, with GLP-1 treatments accounting for approximately 28% of total platform activity, indicating a balanced and diversified approach [3][4] - The company has seen a 72% year-over-year increase in pharmacy orders, reflecting strong demand and treatment continuity [9] - The nurse network and clinic engagement have shown significant growth, with 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year [15] VSDHOne Platform - VSDHOne, launched in June 2025, has recorded approximately 295,000 product orders in Q3 and a total of about 887,000 orders since its launch [11][12] - The company aims to reach a target of approximately 1.3 million product orders for 2025, based on existing partner demand [13] Strategic Initiatives - The company is focused on enhancing its operational infrastructure, compliance, and automation processes as part of its 2026 framework [20][22] - Hydreight is expanding into additional treatment categories, including genetics and oral weight management, while also growing its partner ecosystem across the United States [22] Future Outlook - The company plans to release its 2026 guidance in mid-December, with a focus on stability, scale, and continued engagement with shareholders [23]

Core Insights - Hydreight Technologies Inc. has successfully closed a strategic partnership transaction with Perfect Scripts LLC, acquiring a 5% membership interest in exchange for 2,250,000 common shares valued at CAD$2.30 each [1][2] - The partnership aims to establish a 503B pharmacy in the U.S., allowing Hydreight to secure the lowest pricing for products sold by Perfect Scripts and its subsidiaries [2][8] - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight's expansion [8] Company Overview - Hydreight operates a fully integrated mobile clinical network comprising over 2,500 nurses and 100 doctors across the U.S., providing healthcare services directly to patients [14] - The company has a 503B pharmacy network servicing all 50 states and is closely affiliated with a certified e-script and telemedicine provider network [14] - Hydreight's proprietary platform includes tools for accounting, documentation, sales, inventory, and patient data management, enhancing service delivery [14] Partnership Details - The transaction includes a Pro-Rata Investment Right allowing Hydreight to maintain its interest in Perfect Scripts and an option to acquire up to 40% of its membership interests [2][3] - Restrictions have been placed on the number of Hydreight shares that can be issued to Perfect Scripts, capping total shares at 12,000,000 [3] - A cash finder's fee of $258,750 was paid, representing 5% of the transaction's deemed value [4] Perfect Scripts Overview - Perfect Scripts LLC is the parent company of PerfectRx LLC and operates a 503A retail pharmacy in Iowa, with a distribution center in Florida [9][10] - PerfectRx is a HIPAA-compliant mail-order pharmacy capable of processing over 150,000 prescriptions daily, with infrastructure to handle demand surges [10][11] - The company utilizes its proprietary PerfectOS platform for digital prescription intake and real-time inventory management [10][11]

Core Insights - Hydreight Technologies Inc. reported significant financial growth in Q3 2025, with a focus on expanding its VSDHOne platform and achieving strategic objectives for 2026 [1][5][10] Financial Performance - For the first nine months of 2025, topline revenue reached CAD 26.71 million, a 61% increase year-over-year, while GAAP revenue was CAD 20.44 million, up 70% [5][7] - Q3 2025 topline revenue was CAD 12.83 million, marking a 110% increase compared to Q3 2024, with GAAP revenue at CAD 10.52 million, a 132% increase [5][7] - Q3 2025 gross margin improved to CAD 2.33 million from CAD 1.53 million in Q3 2024, and adjusted EBITDA was CAD 620K, indicating continued operational improvement [5][7] - The company reported a GAAP net income of CAD 362K in Q3 2025, a significant turnaround from a net loss of CAD 90K in Q3 2024 [5][7] Business Development - Hydreight processed approximately 295,000 VSDHOne product orders between July and September 2025, reflecting broad growth across various wellness verticals [5][10] - The nurse network expanded with 198 new sign-ups in Q3 2025, a 49% increase year-over-year, totaling 593 sign-ups in the first nine months of 2025, up 63% from 2024 [5][10] - Pharmacy orders increased by approximately 72% year-over-year, indicating sustained growth and broader adoption of services [5][10] Strategic Initiatives - The company signed a definitive agreement to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][10] - Hydreight is actively evaluating profitable multi-state wellness and digital health operators for potential acquisitions to scale nationally through the VSDHOne platform [5][10] - The upcoming release of VSDHOne V2 aims to enhance automation, scalability, and modular functionality for partners nationwide [5][10] Recognition and Awards - Hydreight was recognized as one of Canada's Technology Fast 50™ award winners and ranked 77 among the fastest-growing companies in North America on the 2025 Deloitte Technology Fast 500™ [5][10]

Core Insights - Hydreight Technologies Inc. ranked No. 77 on the 2025 Deloitte Technology Fast 500™, highlighting its status as one of the fastest-growing technology companies in North America [1][2] - The company's growth is attributed to the expansion of its telehealth and pharmacy infrastructure, as well as the rapid onboarding of partners to its VSDHOne direct-to-consumer platform [2] - Hydreight previously ranked 56 on the 2024 Deloitte Technology Fast 500™ and 9 on Deloitte's 2024 Technology Fast 50™ (Canada) [2] Company Overview - Hydreight is building a large mobile clinic network in the United States, with a platform that includes over 3,000 nurses and 200 doctors across all 50 states [6][7] - The platform offers integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, enabling healthcare professionals to provide services directly to patients [7] - The company has a 503B pharmacy network and is affiliated with a certified e-script and telemedicine provider network [7] VSDHOne Platform - The VSDHOne platform simplifies entry for healthcare and wellness brands into the online space, allowing them to launch nationwide in days [8] - Compliant offerings include GLP-1s, peptides, personalized healthcare treatments, and more [8] - The platform provides a complete solution for businesses looking to enter the direct-to-consumer healthcare market, significantly reducing time and costs associated with launching services [8] Industry Context - The 2025 Technology Fast 500 companies achieved revenue growth ranging from 122% to 29,738%, with an average growth rate of 1,079% over three years [3] - The Deloitte Technology Fast 500™ has been recognizing fast-growing companies for 31 years, emphasizing the agility of private enterprises in competitive markets [4]

Core Insights - Hydreight Technologies Inc. has reported significant growth, processing over 295,000 VSDHOne product orders from July to September 2025, indicating a robust expansion in its nurse network and a strong financial position with approximately CA$18.7 million in cash [1][6][9]. Company Performance - The company ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada for revenue growth from 2021 to 2024, and previously ranked 56 on Deloitte's 2024 Technology Fast 500™ in the U.S., highlighting its leadership in modernizing healthcare delivery through technology [3][6]. - Hydreight operates one of the largest compliant telehealth and medical networks in the U.S., connecting healthcare providers, pharmacies, and patients through its VSDHOne platform across all 50 states [4][13]. Recent Highlights - The company saw a 49% year-over-year increase in new nurse sign-ups, with 198 new sign-ups between July and September 2025 compared to 133 in the same period last year, and a total of 593 sign-ups in the first nine months of 2025, up from 364 in 2024 [9]. - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, reflecting sustained growth across multiple wellness verticals [9]. Financial Position - Hydreight enhanced its liquidity with an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing its cash position to approximately CA$18.7 million as of October 22, 2025 [9][12]. - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value while scaling its telehealth infrastructure nationally [12]. Strategic Initiatives - The company is actively integrating 503A/503B pharmacy partners to improve capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9]. - Hydreight is expanding its GLP-1 program and direct-to-consumer wellness offerings, with ongoing national rollout initiatives [10][9]. Industry Recognition - Hydreight has been recognized as a Top 50 TSX Venture Exchange Company for 2024 and selected as a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8].

Core Insights - Hydreight Technologies Inc. has reported significant growth in product orders and nurse network expansion, with over 295,000 VSDHOne product orders processed between July and September 2025, indicating a strong demand for its services [1][9] - The company has a robust cash position of approximately CA$18.7 million, positioning it well for future growth initiatives [6][9] - Hydreight has received multiple recognitions for its rapid growth and innovation, including being ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada [3][8] Company Performance - The company processed ~295,000 VSDHOne product orders from July to September 2025, reflecting broad growth across various wellness verticals [9] - Nurse network expansion saw 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year, and a total of 593 sign-ups in the first nine months of 2025, up ~63% from 2024 [9] - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, indicating sustained growth and broader adoption [9] Financial Position - Hydreight's liquidity was enhanced by an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing cash reserves to approximately CA$18.7 million as of October 22, 2025 [9] - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value [12] Strategic Developments - Hydreight is actively integrating 503A/503B pharmacy partners to improve capacity and fulfillment speed, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9] - The company is rolling out Dr. Franklin Joseph's GLP-1 program nationally to meet increasing patient demand [10] - Hydreight is evaluating potential mergers and acquisitions of profitable multi-state wellness and digital health operators to scale nationally [9] Industry Recognition - Hydreight was recognized as a Top 50 TSX Venture Exchange Company for 2024 and was a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8] - The company has been acknowledged for its leadership in modernizing healthcare delivery through technology and compliance [3]

Core Insights - Hydreight Technologies Inc. has reported stronger-than-expected order growth and strategic advancements, indicating a robust performance in the mobile clinical network sector [1][2][3] Order Growth and Market Momentum - In August 2025, Hydreight processed over 80,000 pharmacy and telehealth product orders, exceeding the internal forecast of approximately 55,000 orders, reflecting broad demand across multiple service lines [2] - The company has seen an 86% year-over-year increase in pharmacy orders from January to August 2025, indicating significant market momentum [3] Strategic Growth Initiatives - Hydreight has invested in making the VSDHOne platform fully modular, enhancing customer adoption and expanding its total addressable market [4] - The company reported a 33% year-over-year revenue growth for H1 2025, marking its third consecutive quarter of profitability, driven by strong pharmacy order growth and network expansion [4] - An oversubscribed financing round raised $11.5 million to support strategic initiatives and strengthen the balance sheet [4] - The acquisition of a 5% stake in Perfect Scripts LLC aims to enhance operational control over pharmacy fulfillment and support margin expansion [4] AI Integration - Hydreight is in due diligence to acquire an AI-driven tool designed to provide personalized IV treatment recommendations, which is expected to enhance clinical decision-making and marketing capabilities [5] Customer Lifetime Value (LTV) Expansion - The company is focusing on expanding Customer Lifetime Value (LTV) by encouraging patients to engage with multiple service offerings within its ecosystem, thereby deepening patient relationships and improving unit economics [6] Outlook - Management emphasizes the need for continued investment in infrastructure, technology, and regulatory compliance to sustain growth, particularly in integrating new acquisitions [7] Competitive Position - Hydreight believes its established provider network, expanding pharmacy relationships, and growing patient demand position it favorably in the fragmented U.S. digital health market [8] Management Commentary - The CEO highlighted the broad-based adoption of Hydreight's services across various healthcare segments, indicating a strong platform performance [9] - The company is committed to building a scalable and compliant model that delivers value to patients, providers, and shareholders [10]